# Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance

> **NCT06747507** · PHASE3 · RECRUITING · sponsor: **University of Nairobi** · enrollment: 392 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Dolutegravir Pill
- **DRUG:** Darunavir+Ritonavir

## Key facts

- **NCT ID:** NCT06747507
- **Lead sponsor:** University of Nairobi
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-07
- **Target enrollment:** 392 (ESTIMATED)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06747507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06747507, "Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06747507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*